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Increased Matrix Synthesis Following Adenoviral Transfer 
of a Transforming Growth Factor PI Gene 
into Articular Chondrocytes 
"Franklin D. Shuler, *Helga I. Georgescu, "Christopher Niyibizi, *Rebecca K. Studer, 
TZhibao Mi, $Brian Johnstone, ?Paul D. Robbins, and *?Christopher H. Evans 
Departnzents of *Orthopuedic Surgery and fMolecidnr Genetics and Biochemistry, 
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, and $Department of 
Orthopedic Surgery, Case Wesfern Reserve University, Clevelandj Ohio, U.S.A. 
Summary: Monolayer cultures of lapine articular chondrocytes were transduced with first-generation adeno- 
viral vectors carrying lacZ or transforming growth factor PI genes under the transcriptional control of the 
human cytomegalovirus early promoter. High conccntrations of transforming growth factor PI were produced 
by chondrocytes following transfer of the transforming growth factor P, gene but not the lacZ gene. Trans- 
duced chondrocytes responded to the elevated cndogenous production of transforming growth factor PI by 
increasing their synthesis of proteoglycan, collagen, and noncollagenous proteins in a dose-dependent fash- 
ion. The increases in collagen synthesis were not accompanied by alterations in the collagen phenotype; type- 
I1 collagen remained the predominant collagen. Transforming growth factor PI could not, however, rescue 
the collagen phenotype of cells that had undergone phenotypic modulation as a result of scrial passaging. 
These data demonstrate that chondrocytes can be genetically manipulated to produce and respond lo the po- 
tentially therapeutic cytokine transforming growth factor PI. This technology has a number of experimental 
and therapeutic applications, including those related to the study and treatment of arthritis and cartilage 
repair. 
Articular cartilage has a limited capacity to repair 
damage sustained as a result of disease or  injury (25). 
Although there are a variety of surgical and pharma- 
cological approaches to  enhancing cartilage repair, 
none is ideal (25). Improvements in understanding the 
biology of articular chondrocytes have provided op- 
portunities for improving the healing of articular car- 
tilage by biological means. An attractive example of 
this approach is to employ cytokines that increase ma- 
trix synthesis, decrease matrix breakdown, or do  both 
(8,25,3 1). 
Although such molecules hold much promise in this 
regard, their clinical application is likely to be limited 
by problems associated with the need for maintaining 
high concentrations of these cytokines at sites of carti- 
lage damage for sustained periods of time. Direct ap- 
plication of the substances themselves may not be 
useful because of their short biological half-lives. For 
example, it was recently reported that the half-life of 
bone morphogenetic protein-2 (BMP-2) introduced 
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into an expcrimental lesion in the articular cartilage of 
rabbit knee joints is 4 days (14). One approach to solv- 
ing this sort of problem involves the implantation of a 
matrix that releases the factor at biologically relevant 
concentrations. Gene transfer offers an alternative 
approach (9). 
Cytokines are proteins, and there are several po- 
tential advantages to delivering to cartilage the genes 
encoding therapeutic cytokines rather than the cyto- 
kines theinselves (9). One advantage is that the repar- 
ative factors are synthesized locally in a sustained and 
potentially regulatable fashion at the site of injury. 
And, unlike recombinant factors produced by bacte- 
ria, those synthesized endogenously as a result of gene 
transfer have undergone authentic post-translational 
modification and may therefore have improved po- 
tencies. The feasibility of transferring genes to  experi- 
mental lesions within articular cartilage has already 
been demonstrated (5,20). 
Transforming growth factor PI (TGF-PI) is a pow- 
erful modulator of cartilage metabolism, which can 
promote matrix synthesis, inhibit matrix catabolism, 
and alter chondrocyte proliferation rates in vitro and 
in vivo (1 8,23,24,26,28,29,34). Moreover, TGF-P1 can 
counteract the suppressive effects of inflammatory 
586 E D. SHULER ET AL. 
mediators such as interleukin-1 (IL-1) on proteogly- 
can synthesis in cartilage (32,34). TGF-P1 stimulates 
replenishment of proteoglycans in depleted cartilage 
in vivo (34), and osteoarthritic cartilage is more sen- 
sitive to TGF-/3 stimulation than is normal healthy 
cartilage (21). Thus, TGF-P1may be well suited for use 
in the repair of cartilaginous lesions resulting from ar- 
thritis or injury. Despite the beneficial effects of TGF- 
P on cartilage, however, its effects on synovium are 
deleterious. As a result, the direct introduction of 
TGF-P,protein or genes (1,12,13,33,34) into joints can 
be highly inflammatory and fibrotic, leading to carti- 
lage degeneration and osteophyte formation. In view 
of these properties, it is necessary to deliver TGF-P in- 
tracartilaginously under conditions in which the syn- 
ovium is not exposed to this cytokine. The present 
study therefore focuses on delivering the gene for 
TGF-P1 to articular chondrocytes with use of an ade- 
noviral gene transfer system. 
MATERIALS AND METHODS 
Cell Isolation and Transduction 
Articular cartilage was recovered from the knee and shoulder 
joints of young adult (approximately 6 months old) New Zealand 
White rabbits and diced into small pieces (15). Chondrocytes were 
adenovirus or created with human TGF-P1 protein purified from 
platelets (R and D Systems, Minneapolis, MN, U.S.A.). First- 
generation adenoviruses (AEI and AE3) containing a human 
TGF-P1 gene or, as a control, the lacZ gene, under the transcrip- 
tional control of human cytomcgalovirus early promoter were 
generated through Cre-lox recombination (I 6 )  and propagated in 
293 cclls (American Type Culture Collection [ATCC], Rockville, 
MD, U.S.A.). The virus containing the lacZ gene was used to as- 
sess the susceptibility of the cells to adenoviral transduction and 
as a control for the effects of the TGF-P1 gene. 
Transduction of cells with adenovirus containing the lacZ gene 
(AdlacZ) or cDNA encoding human TGF'-Bl (AdTGF-PI) was 
perfornicd in 300 p1 of  Gey's balanced salt solution for 1 hour at 
37°C at various multiplicities of infection. Following transduction, 
thc remaining supernatant was removed and replaced with 1 ml 
of serum-free Neuman-Tytell medium (GIBCO BRL. Grand Is- 
land, NY, 1J.S.A.) supplemented with antibiotics or Ham's F12 
medium supplemented with 10% fetal bovinc serum and antihiot- 
ics (GrBco BRL). Cells serving as untransduced controls were 
treated in the same manner as adenovirally transduced cells. To 
assess the expression of P-galactosidase, the product of the lacZ 
gene, cells were stained with 0.1% X-gal (5-bromo-4-chloro-3- 
indolyl-B-D-galactose; Sigma Chemical, St. Louis, MO, U.S.A.) 48 
hours after transduction by standard methods. The percentage of 
the cells expressing lacZ was determined by visual inspection. 
Nontransduced confluent cells were treated with purified TGF-PI 
protein in scruni-less Neuman-Tytell medium. Following the trans- 
duction of cells or the addition of purified protein to serum-less 
medium, the cells wcrc incubated for 24 hours before the addition 
of radionuclides uscd to determine the synthesis of matrix compo- 
Control 1 MOT 5MOI 
Q Bioassay 
1 ELISA 
ELTSA (no activation) 
FIG. 1. Production of transforming growth factor P1 (TGF-Pl) by chondrocytes. Supernatant from control cells and cells transduced with 
increasing amounts of adenovirus containing cDNA encoding human TGF-PI (AdTGF-B,) were recovered. Latent TGF-PI was activated 
by heating. Active TGF-PI was assayed by enzyme-linked immunosorbent assay (ELISA) and bioassay. In all assays, unlransduced control 
cells produced negligible amounts of TGF-P1. Supernatants from cells transduccd with adenovirus containing the lacZ gene (AdlacZ) also 
produced negligible amounts of TGF-P1 (data not shown). MOT = multiplicity of infection. 
released by the sequential digestion of the cartilage fragments 
with trypsin (2% wtivol; 30 minutes) and collagenase (2% wtivol; 
3 hours). The chondrocytes were seeded into monolayer culture 
at a density of lo5 cellsicm' on 24-well plates with use of Ham's 
F12 nutrient medium supplemented with 10% fetal bovine serum 
and 1 % penicillin-streptomycin in a humidified atmosphere of 5%" 
C 0 2  at 37°C. For most experiments, cells wcre used without pas- 
saging. In those experiments in which thc cffects of passaging 
were evaluated, confluent monolayers were trypsinized (0.2% 
trypsin; 30 minutes), washed, and rcseeded into nutrient medium 
at a 1:2 split ratio. This process was rcpcated to generate third- 
passage cells. 
Two treatment groups comprised cells either transduced with 
nents. Expcriments were run in duplicate (i.e., n = 2 for each ex- 
periment). Each experiment was run at least twice (i.e,, total n = 
4) or three times (i.e., total n = 6) .  
Determination of TGF-PI Concentration 
Latent TGF-P, was converted to activc TGF-B1 by healing the 
sample at 80°C for 15 minutes. TGF-P, concentrations in con- 
ditioned media were determined with a commercially available 
enzyme-linked immunosorbent assay (ELTSA) kit and protocol 
(R and D Systems) and by the mink lung cell bioassay (19). 
The ELISA protocol is a sandwich assay in which samples are 
added to 96-well plates coated with the type-IT TGF-P soluble re- 
ceptor. This captures any TGF-P, in the sample, which is detected 
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FIG. 2. Proteoglycan synthesis in response to transforming growth Cactor PI (TGF-PI) (A) exogenously applied protein and (B) en- 
dogenously synthesized by transduced cells. A: Exogcnous TGF-PI. Confluent chondrocytes were treated with different cmccntrations 
of purified, active TGF-0, for a total of 48 hours prior to determination of protcoglycan synthesis. The growth factor was replenished in 
the serum-free media after 24 hours. A dose-dependent increase in proteoglycan synthesis was obtained with increasing conccntrations 
of TGF-P1. The individual data points are averages from triplicate experiments (n = 6) with results reported as mean ? SD. B Endog- 
enous TGF-0,. Confluent chondrocytcs were transduced with adenovirus containing the lacZ gene or cDNA encoding human TGF-0, 
(AdlacZ or AdTGF-PI) in the concentrations indicated and subsequently maintained for 48 hours in serum-free media or media con- 
taining 10% fetal calf scrum. Mean -t SD of triplicate experiments (n = 6) are shown. GAG = glycosaminoglycan, and MOI = multiplicity 
of infection. 
by an anti-TGF-PI antibody covalently linked to peroxidasc. A 
colorimetric assay is used to measure the activity of the bound 
peroxidase, which is converted to TGF-(3, concentration by a stan- 
dard line. The assay fails to detect latent TGF-PI because the 
epitopes recognized by the enzyme-linked antibody are hidden by 
the latency-associated protein. 
For the bioassay, bovine serum albumin (1 ngiml) and 1 pgiml 
of each of the proteinase inhibitors aprotinin, leupeptin, and 
pepstatin were added to conditioned nicdia. Mink lung epithelial 
cells (American Type Culture Collection [ATCC]) were seeded 
into 24-well plates with minimal Eagle medium supplemented 
with 10% fetal bovine serum, serum antibiotics, and glutamine. 
Six hours later, the medium was changed to one with only 0.5% 
fetal bovine scrum and the culture continued for 18 hours. At 
this time, the chondrocyte-conditioned media or purified TGF- 
PI standards were added and incubation continued for an ad- 
ditional 6 hours. The cultures wcrc then pulse-labeled with 
[3H]thymidine lor 2 hours, and the incorporation of radioactivity 
into material precipitated by trichloroacetic acid was measured 
by liquid scintillation. 
Proteoglycan and Collagen Synthesis 
To determinc the effect of TGF-P1 on matrix production, the 
synthesis of protcoglycan by adenovirally transduced chondro- 
cytes and chondrocytes treated with exogenously added TGF- 
PI was measured. The synthesis of proteoglycans was measured 
as the incorporation of ”SO:- into glycosaminoglycans (30). 
Na2[”S]O:- (40 pCi[1,480 X lo3 Bqliml) was added to the cul- 
tures, and incubation continued for an additional 8 hours. The 
cells and media were then extracted with 4 M guanidinium 
hydrochloride. and the radioactivity incorporatcd into pro- 
teoglycans was separated from unincorporated precursor by 
size-exclusion chromatography on PD-10 columns (Pharmacia, 
Piscataway. NJ, U.S.A.). 
[‘Hlproline was used to label newly synthesized collagen and 
noncollagenous proteins (7). Cells were incubated for 24 hours 
with 5 pCi(l85 X lo3 Bq)/ml [3H]proline (specific activity 55 
Ci[2,035 X lo9 Bq]/mmol). At the end of the incubation period, 
newly synthesized proteins were recovered from the medium and 
cell layer and digcsted with highly purified collagenase ABC form 
IT1 (Advanced Biofacturcs, Lynbrook, NY, U.S.A.) producing a 
soluble fraction reprcscnting collagen production. Collagenase- 
resistant matcrial was digested with papain to release radioactiv- 
ity incorporated into noncollagenous proteins. Because TGF-0, 
has been reported to increase the production of type-I collagen 
in other cell types (18,27), collagen phenotyping was performed 
to analyze the types of collagens produced in basal and TGF-PI- 
stimulated states. Collagen phenotyping was performed by a pre- 
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FIG. 3. Synthesis of collagen and noncollagenous proteins by chondrocytes in response to transforming growth factor PI  (TGF-PI ) (A) ex- 
ogenously added protein and (&) endogenously synthesized by transdueed cells. A Exogenous TGF-PI. Confluent cells were treated with 
different concentrations of purified, active TGF-P,for a total of 48 hours prior to determination of proteoglycan synthesis. The growth fac- 
tor was replenished in the scrum-free media after 24 hours. Data points are means of triplicate experiments (n = 6) i SD. B: Endogenous 
TGF-pI. Confluent chondrocytes were transduced with adenovirus containing the lacZ gene or eDNA encoding human TGF-PI (AdlacZ 
or AdTGF-PI) at the multiplicities of infection (MOI) indicated and subsequently grown for 48 hours prior to determination of collagen 
and noncollagenous protein synthesis. Means of duplicate experiments (n = 4) are shown. 
viously described method ( 7 )  following the separation of samples 
by sodium dodccyl sulfate-polyacrylaniide gel electrophoresis 
(SDS-PAGE) on 7.5% gels. Briefly, extracts were treated with 
pepsin (100 pgiml) in 0.5 M acetic acid and digested for 4 hours. 
The digests were dialyzed against 0.05 M NH,HCO1, dried, and 
analyzed by SDS-PAGE. Gels were treated with EN’HANCE 
(DuPont-NEN, Boston, MA, U.S.A.) prior to autoradiography. 
Densitometric analysis of autoradiograms was performed to de- 
termine the relative abundance of type-I and type-I1 collagen with 
the BIO-RAD GS-670 imaging densitometer (Bio-Rad Laborato- 
ries, Richmond, CA, U.S.A.). The positions of al(1) and ul(I1) 
chain migration on the gels were determined with purified type-I 
and type-I1 collagen run as standards on the same gels. 
Matrix Metalloproteinase (MMP) Assays 
Conditioned media were assayed for collagenase, gelatinase, 
and stromelysin with use of radiolabeled substrates (3). Casein 
(Sigma Chemical) and type-I bovine collagen (Vitrogen; Collagen 
Corporation, Palo Alto. CA, U.S.A.) were radiolabeled with triti- 
atcd acetic anhydride. Aliquots of [3H]collagen were heated to 
60°C for 30 minutes to form gelatin. Assays were run in reaction 
buffer containing SO mM Tris, 0.2 M NaCI. and 5 mM CaCl,, pH 
7.4. Assay mixes contained 50 p1 radioactive substrate, 50 p1 con- 
ditioned media, and 100 pl reaction buffer. Aminophenylmercuric 
acetate (1 mM) was added to activate latent enzyme. Reactions 
were allowed to proceed for 4 hours at 37°C for caseinase (pre- 
dominantly stromelysin) and gelatinase and 25°C for collagenase 
activity. The reactions werc terminated by the addition of 250 pl 
10% trichloroaeetic acid, and thc radioactivities of the trichloro- 
acetic acid soluble material were measured by liquid scintillation. 
RESULTS 
With use of a multiplicity of infection of 50, essen- 
tially all chondrocytes were positive for lacZ (data not 
shown). No toxicity was observed at any multiplicity 
of infection. Naive cells did not secrete detectable 
amounts of MMPs, and transduction of cells with ade- 
novirus did not induce collagenase, gelatinase, or 
stromelysin activities (data not shown). 
Cells infected with AdTGF-P1 produced elevated 
amounts of TGF-P1 protein as determined by ELISA 
(Fig. 1). Estimates of TGF-PI concentration by the 
mink lung cell bioassay provided values in close 
J Orthop Res, Vol. 18, No. 4, 2000 
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FIG. 4. Quantitativc and qualitative effects of transduction with adenovirus containing cDNA encoding human transforming growth factor 
PI (AdTGF-PI) on the collagen produced by chondrocytes. A Coomassie blue-stained gel reveals the presence of a major collagen band 
migrating in the al(I)/al(II) position. Autoradiography (inset) shows that in addition to type-I1 collagen chains, the newly synthesized col- 
lagen is composed of bands that co-migrate with al(V)la,(XI) and a&) chains. B: Densitometric scanning of protein bands on autorad- 
iograms confirms an increase in collagen synthesis in response to TGF-PI produced by transduced chondrocytes. Values under each 
individual lane represent the amount of collagen synthesized, based on a control value o f  100% (lane 1). C: Equal amounts of radioactive 
collagen (50,000 cpm/well) were loaded and separated on a 7.5”/0 sodium dodecyl sulfate-polyacrylamide electrophoresis gel. Equal band 
intensities were obtained regardless of treatment. Densitometric scanning of the protein bands confirmed that 80% of the newly synthe- 
sized collagen was type 11. The percentage of type-I1 collagen is given under each individual lane. In each panel, lanes 2-6 represent cells 
with increasing multiplicities of infection (MOI) of AdTGF-PI 
agreement with the ELISA data. Most of the TGF-P1 
in the conditioned media was latent (Fig. 1). 
The addition of TGF-PI to cells maintained under 
serum-free conditions produced a dose-dependent, 
saturable response with a 225 % increase in proteogly- 
can synthesis obtained with 2.5 ng/ml TGF-P1 (Fig. 2). 
Cells transduccd with AdTGF-D, also synthesized 
proteoglycans at elevated rates, with 1 multiplicity of 
infection increasing production to 175% of control 
and 5 multiplicities of infection increasing production 
to 275 % of control (Fig. 2B). These levels of stimula- 
tion are approximately equal to those obtained with 
the addition of purified protein at the concentrations 
achieved by gene transfer. The use of an adenoviral 
J Orzhop Res, Vol. 18, No. 4, 2000 
590 I? D. SHULER ET AL. 
control (AdlacZ) demonstrated that the effect was 
due to the presence of TGF-P1 and not to the adenovi- 
ral transfection protocol. The stimulatory effect of the 
TGF-P1 transgene was potentiated in the presence of 
10% fetal bovine serum with the lowest concentration 
of virus, AdTGF-8, at 1 multiplicity of infection, in- 
creasing production 3-fold (Fig. 2B, serum). 
TGF-P1 also increased the synthesis of collagen and 
noncollagenous proteins in a dose-dependent, satura- 
ble fashion (Fig. 3A). Maximal increases in protein 
synthesis were obtained with 1.25 to 2.5 ng/ml TGF- 
P1, elevating the synthesis of collagen and noncollage- 
nous protein to 362 and 353% of control, respectively. 
Adenovirally induced production of TGF-P1 resulted 
in a dose-dependent increase in collagen (Fig. 3B) and 
noncollagenous protein synthesis. Thus, TGF-P1 pro- 
duced endogenously by chondrocytes as a result of 
gene transfer increased the synthesis of both pro- 
teoglycan and collagen to approximately the same de- 
gree as exogenously applied TGF-P1. 
Separation of collagen molecules on the basis of 
molecular size was performed with SDS-PAGE (Fig. 
4). The type-I1 collagen standard co-migrated with the 
major collagen band produced in untreated and in- 
fected primary chondrocytes. A band corresponding 
to the a2(I) chain was barely visible on these Coo- 
massie blue-stained gels, demonstrating that type-I1 
collagen is the predominant collagen produced in 
these cells. The darker bands at the bottom of the gel 
in Fig. 4A are due to the addition of pepsin. Autora- 
diography was performed to establish the effect of 
TGF-P1 treatment on collagen production. Total col- 
lagen synthesis was assessed, and an autoradiogram is 
shown (Fig. 4B). The increase in the density of bands 
generated after treatment of cells with AdTGF-PI 
confirms that adenovirally induced production of 
TGF-S, is capable of increasing collagen synthesis. 
The greater sensitivity of autoradiography compared 
with staining with Coomassie blue permitted detec- 
tion of a small amount of u2(I) collagen chains. Col- 
lagen phenotyping was performed on gels where 
equal counts were loaded (Fig. 4C). Band intensities 
for type-I and type-I1 collagens did not vary among 
treatment groups; densitometric analysis revealed an 
average of 80% type-I1 collagen produced in all 
groups on the basis of the assumption that the ratio of 
a1 (T):a2(1) chains is 2:l. This is the same percentage 
of type-I1 collagen as made by untreated, unpassaged 
chondrocytes (data not shown). 
In view of the ability of TGF-P1 to increase the syn- 
thesis of collagen by chondrocytes while maintaining 
the predominantly type-TI collagen phenotype, we un- 
dertook a series of experiments to determine whether 
TGF-PI could rescue the collagen phenotype of cells 
that had been serially passaged. In these experiments, 
cells were exposed to TGF-PI from 48 hours to 5 days. 
The representation of type-TI collagen decreased from 
approximately 80% in unpassaged cells to 53% in 
cells at the second passage and 28% in cells at passage 
three (data not shown). The addition of as much as 2 
ngiml TGF-P1 increased total collagen synthesis but 
failed to restore the representation of type-TI collagen 
(data not shown). The TGF-P3 isoform was also un- 
able to elevate the proportion of type-I1 collagen syn- 
thesized by these cells (data not shown). Because 
TGF-P protein had no effect on the collagen pheno- 
type of the passaged cells, experiments with trans- 
duced cells were not attempted. 
DISCUSSION 
These data confirm that articular chondrocytes are 
susceptible to transduction with adenoviral vectors, 
efficiently express a TGF-P1 transgene delivered by 
such vectors, and respond to the secreted product by 
increasing matrix synthesis. The increment in matrix 
synthesis resulting from transgene expression was ap- 
proximately equal to that achieved by adding a similar 
amount of purified human TGF-PI. Importantly, col- 
lagen synthesized in the presence of TGF-P1 remained 
predominantly type 11; it is well known that excessive 
production of type-I collagen leads to defective repair 
tissue that ultimately fails. Although TGF-P1 was able 
to maintain the collagen phenotype of unpassaged 
cells, it could not rescue that of passaged cells, which 
produce predominantly type-I collagen. This observa- 
tion is of relevance to the use of autologous chondro- 
cyte transplants in repairing cartilaginous defects, 
where the cells undergo multiple cell divisions before 
reimplantation (6). 
While this work was in progress, Arai et a]. (2) re- 
ported complementary studies in which adenoviral 
transfer of a TGF-PI gene to a human chondrocytic 
cell line in vitro increased the abundance of aggrecan 
core protein mRNA while decreasing the abundance 
of stromelysin mRNA. They did not study collagen 
gene expression. As well as promoting the repair of 
cartilaginous lesions produced by trauma, the TGF-P1 
gene may be particularly useful in osteoarthritis, 
where the chondrocytes are hyper-responsive to TGF- 
PI (21). This is the opposite of their response to 
insulin-like growth factor-1 (IGF-l), which is de- 
pressed in osteoarthritis (22). 
The intraarticular activity of TGF-P needs to be 
carefully controlled. Intraarticular injection of TGF-P 
protein, or delivery of AdTGF-P to the synovium, 
leads to inflammation, osteophyte formation, fibrosis, 
and cartilage erosions (1,12,33,34). Tn contrast. trans- 
fer of the TGF-PI gene to a limited number of cells 
within a cartilaginous lesion should allow for the local 
production of TGF-P1, the concentration of which will 
be high within the lesion but extremely low elsewhere. 
In this way, cartilage repair could be accelerated 
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without provoking additional adverse intraarticular 
disturbances. 
Clearly, this approach can be used with genes other 
than TGF-PI. A variety of interesting growth factors, 
including certain members of the BMPs, fibroblast 
growth factor, IGF, platelet-derived growth factor, 
and hedgehog families of proteins, await evaluation 
(8). In addition, IL-1 suppresses cartilage repair by 
both inhibiting the synthesis and accelerating the 
breakdown of matrix. Baragi et al. (4) have shown 
that transfer of the IL-1 receptor antagonist (IL-1Ra) 
gene to chondrocytes protects cartilage from the cata- 
bolic effects of IL-1 in vitro. Delivery of the IL-1Ra 
gene to the synovial lining of joints ameliorates exper- 
imental models of rheumatoid arthritis and osteoar- 
thritis (11) and is in a phase-I clinical trial for human 
rheumatoid arthritis (10). 
The data presented in this paper encourage the fur- 
ther development of gene-based methods for preserv- 
ing and repairing articular cartilage. 
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